1-9 of 9
Birte Friedrichs
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II frontline chemolight R-pola-glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma

Free
Björn Chapuy, Rebecca Wurm-Kuczera, Ralph Michael, Meng Wang, Petra Pichler, Angela Huster, Andrea Kerkhoff, Michael Panny, Roland Schroers, Anna Ossami Saidy, Fabian Müller, Frederik Damm, Manuel Orlinger, Philipp Staber, Carsten Schwaenen, Luisa Wohn, Clemens Schmitt, Martin Hoffmann, Mathias Hänel, Johannes Duell, Simone Heyn, Stephanie Mayer, Thomas Weber, Peter Reimer, Natalia Magdalena Rotter, Ulf Schnetzke, Bastian von Tresckow, Gabriel Kammerer, Julia Rasvina, Barbara Lehner, Thomas Mika, David Böckle, Corinna Leng, Anna Lena Illert, Bettina Altmann, Birte Friedrichs, Ella Willenbacher, Dimitrios Mougiakakos, Christiane Pott, Salah-Eddin Al-Batran, Andreas Rosenwald, Dirk Hellwig, Sascha Dietrich, Bertram Glass, Georg Lenz, Ulrich Keller, Marita Ziepert, Thomas Melchardt, Richard Greil
Journal: Blood
Blood (2025) 146 (Supplement 1): 61.
https://doi.org/10.1182/blood-2025-61
Published: 2025
Journal Articles

Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Free
Tatjana Holzer, Stefanie Biedermann, Inga Herfort, Birte Friedrichs, Silke Holtkamp, Linda Hanssens, Mario Assenmacher, Ulf Bethke, Dina Schneider, Stefan Miltenyi, Toon Overstijns, Christoph Schmid, Francis A. Ayuk, Christoph Scheid, Anja Jühling, Udo Holtick, Philipp Gödel, Peter Borchmann, Iris Bürger
Journal: Blood
Blood (2022) 140 (Supplement 1): 4581–4583.
https://doi.org/10.1182/blood-2022-164597
Published: 2022
Journal Articles

Trial in Progress: A Randomized Phase II Study of MB-CART2019.1 Compared to Standard of Care Therapy in Patients with Relapsed/Refractory DLBCL Ineligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation - DALY 2-EU Trial

Free
Peter Borchmann, Peter Vandenberghe, Alvaro Urbano-Ispizua, Corinne Haioun, Francois Lemonnier, Laimonas Griskevicius, Sébastien Maury, Silke Holtkamp, Birte Friedrichs, Gregor Zadoyan, Linda Hanssens, Toon Overstijns, Mario Assenmacher, Ulf Bethke, Iris Bürger, Olaf Reer, Ulrich Jaeger, Marie José Kersten
Journal: Blood
Blood (2022) 140 (Supplement 1): 12784–12785.
https://doi.org/10.1182/blood-2022-164650
Published: 2022
Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Free
Clinical Trials & Observations
Norbert Schmitz, Lorenz Truemper, Krimo Bouabdallah, Marita Ziepert, Mathieu Leclerc, Guillaume Cartron, Arnaud Jaccard, Peter Reimer, Eva Wagner, Martin Wilhelm, Laurence Sanhes, Thierry Lamy, Laurence de Leval, Andreas Rosenwald, Muriel Roussel, Frank Kroschinsky, Walter Lindemann, Peter Dreger, Andreas Viardot, Noël Milpied, Christian Gisselbrecht, Gerald Wulf, Emmanuel Gyan, Philippe Gaulard, Jacques Olivier Bay, Bertram Glass, Viola Poeschel, Gandhi Damaj, David Sibon, Alain Delmer, Karin Bilger, Anne Banos, Mathias Haenel, Martin Dreyling, Bernd Metzner, Ulrich Keller, Friederike Braulke, Birte Friedrichs, Maike Nickelsen, Bettina Altmann, Olivier Tournilhac
Journal: Blood
Blood (2021) 137 (19): 2646–2656.
https://doi.org/10.1182/blood.2020008825
Published: 2021
Includes: Supplemental data
Journal Articles

Successful Treatment of High-Risk and Refractory Acute Myeloid Leukemia with haploidentical Stem Cell Transplantation Plus NK cell therapy

Free
Lutz Uharek, MD, Birte Friedrichs, MD, Axel Nogai, MD, Chiara Gentilini, MD, Nadezda Basara, MD, Dietger Niederwieser, MD, Eckhard Thiel, MD
Journal: Blood
Blood (2010) 116 (21): 2370.
https://doi.org/10.1182/blood.V116.21.2370.2370
Published: 2010
Journal Articles

Long Term Outcome and Late Effects in Patients Transplanted with Filgrastim-Mobilized Blood or Bone Marrow Treated in a Randomized Trial. A Study from the EBMT Late Effects Working Party

Free
Birte Friedrichs, MD, Andre Tichelli, MD, Andrea Bacigalupo, MD, Nigel H. Russell, MD, Tapani Ruutu, MD, Meral Beksac, Gerard Socie, MD, Norbert Schmitz, MD
Journal: Blood
Blood (2008) 112 (11): 451.
https://doi.org/10.1182/blood.V112.11.451.451
Published: 2008
Journal Articles

Humoral Immune Responses against the Immature Laminin Receptor Show Prognostic Significance in Patients with Multiple Myeloma.

Free
Matthias Zeis, Sandra Siegel, Birte Friedrichs, Norbert Schmitz, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 1534.
https://doi.org/10.1182/blood.V112.11.1534.1534
Published: 2008
Journal Articles

Humoral Immune Responses Against the Oncofetal-Antigen/Immature Laminin Receptor (OFA/iLR) in Patients with Chronic Lymphocytic Leukemia.

Free
Birte Friedrichs, MD, Sandra Siegel, Norbert Schmitz, MD, Matthias Zeis, MD
Journal: Blood
Blood (2006) 108 (11): 2820.
https://doi.org/10.1182/blood.V108.11.2820.2820
Published: 2006
Journal Articles

Rituximab during Pregnancy: Serum Levels, B Cell Counts and Immunoglobulin Levels in Mother and Child.

Free
Birte Friedrichs, MD, Markus Tiemann, MD, Michael K. Wenger, MD, Karl Verpoort, MD, Norbert Schmitz, MD
Journal: Blood
Blood (2005) 106 (11): 1508.
https://doi.org/10.1182/blood.V106.11.1508.1508
Published: 2005